Drug Target Review

Blocking growth hormone may improve resistant lung cancer treatment

Explore new strategies for treating resistant lung cancer. Discover how blocking growth hormone receptors may improve ...
Endocrinology Advisor

Sogroya Approval Expanded to Include 3 Additional Pediatric Growth Disorders

FDA expands Sogroya approval for pediatric patients with Noonan syndrome, idiopathic short stature, and those born small for gestational age.
News-Medical.Net

Blocking growth hormone receptor may improve treatment response in lung cancer

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments.

Growth hormone receptor could serve as possible target for improving lung cancer treatment

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other ...
EurekAlert!

New study identifies growth hormone receptor as possible target to improve lung cancer treatment

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments. The study published in the International Journal of Molecular Science ...

FDA approves Novo Nordisk's Sogroya(R) as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...